Press release: Q3: continued sales and earnings progress

(Paris:SAN), Q3: continued sales and earnings progress Paris, October 24, 2025 Q3 sales growth of 7.0% at CER1 and business earnings per share (EPS)2 of EUR2.91 Pharma launches increased sales by 57.1%, reaching EUR1.0 billion, driven by ALTUVIIIO and Ayvakit Dupixent sales increased by 26.2% to EUR4.2 billion, first time above EUR4 billion in a […]

Press release: Q3: continued sales and earnings progress

Press release: Q3: continued sales and earnings progress GlobeNewswire October 24, 2025 Q3: continued sales and earnings progress Paris, October 24, 2025 Q3 sales growth of 7.0% at CER1 and business earnings per share (EPS)2 of EUR2.91 Pharma launches increased sales by 57.1%, reaching EUR1.0 billion, driven by ALTUVIIIO and Ayvakit Dupixent sales increased by

Carrier Hong Kong Marks 75 Years of Achievement, Commits to Leading Intelligent Climate and Energy Solutions, and Launches New Corporate Brand Identity: “For the World We Share”

Built on Willis Carrier's invention of modern air conditioning in 1902, Carrier constantly build upon our history of proven innovation with new products and services that improve global comfort and efficiency. Carrier proudly commemorated its 75th anniversary in Hong Kong with a grand anniversary gala at The Peninsula Hong Kong on 17 October. The event

Global Media First Drive of G700: A Comprehensive Validation of GAIA Hybrid Off-Road Architecture

WUHU, China, Oct. 24, 2025 (GLOBE NEWSWIRE) — The world's leading automotive journalists gathered at Anhui's Hongyangshan Automotive Sports Park for the first drive of the all-new G700. The event, under the banner “Innovation – Defining the Future,” offered a firsthand look at the GAIA Hybrid Off-Road Architecture. Smart Off-Road System: Effortless Control All Terrains

Global Media First Drive of G700: A Comprehensive Validation of GAIA Hybrid Off-Road Architecture

Global Media First Drive of G700: A Comprehensive Validation of GAIA Hybrid Off-Road Architecture GlobeNewswire October 24, 2025 WUHU, China, Oct. 24, 2025 (GLOBE NEWSWIRE) — The world's leading automotive journalists gathered at Anhui's Hongyangshan Automotive Sports Park for the first drive of the all-new G700. The event, under the banner “Innovation – Defining the

LEPAS Elegant Technology, Defined by You: LEPAS Fun Test Drive Interprets a New Paradigm for Intelligent Driving via User Co-Creation

From October 18 to 19, theLEPAS Fun Test Drive event successfully took place, following the Global Journey of Elegant Driving (China Stop) that concluded on October 15. Together, the two events showcased LEPAS's strength across multiple scenarios and deepened guests' understanding of its positioning as the “Preferred Brand for Elegant Mobility Life.” https://mma.prnewswire.com/media/2803727/image.jpg Media, KOLs,

Norsk Hydro: Solid results amid uncertain markets

(Irish:IRSH),(Oslo Bors:NHY77),(Oslo Bors:NHY),(Oslo Bors:NHY78),(Oslo Bors:NHY01),(OTC US:NHYDY),(OTCQX:NHYDY),(Irish:IRSH), Hydro's adjusted EBITDA for the third quarter of 2025 was NOK 5,996 million, down from NOK 7,367 million in the same quarter last year. The results decreased from lower realized alumina prices and a stronger NOK. This was partly offset by higher primary and alumina volumes, positive gain from

Norsk Hydro: Solid results amid uncertain markets

Norsk Hydro: Solid results amid uncertain markets GlobeNewswire October 24, 2025 Hydro's adjusted EBITDA for the third quarter of 2025 was NOK 5,996 million, down from NOK 7,367 million in the same quarter last year. The results decreased from lower realized alumina prices and a stronger NOK. This was partly offset by higher primary and

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/avB6 Bispecfic ADC JSKN022

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I clinical study (Study ID: JSKN022-101) of JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin avB6, for the treatment of advanced malignant solid tumors. JSKN022 is the

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

(NASDAQ:XFOR), BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the pricing of its previously announced underwritten public offering of 45,860,000 shares of its common stock at a public offering price per share of

Scroll to Top